Live Analyst Rating Changes 34764 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Matthew Caufield
HC

Matthew Caufield

H.C. Wainwright
Wall Street Analyst
★★★☆☆
#1703
on 13Foresight · ranked by our own returns
42%
Success Rate
-0.7%
Average Return
22 of 53 calls profitable · +27.8% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 42% of Matthew Caufield's ratings turned a profit when each position was held for 1 year — averaging -0.7% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

115 Buy 6 Hold 0 Sell
Matthew's Stock Coverage 21 ratings · 2026-09-26
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
SRZN
Surrozen
 Sep 25, 2026 BUY Strong Buy
+24.8% avg upside
8 analysts
$54.00
82.84% Upside
 · ·
ZBIO
Zenas BioPharma, Inc.
 Sep 21, 2026 BUY Strong Buy
+57.1% avg upside
11 analysts
$44.00
63.20% Upside
 -17.2% ·
PHAT
Phathom Pharmaceuticals
 Sep 21, 2026 BUY Strong Buy
+241.3% avg upside
15 analysts
$26.00
256.16% Upside
 +0.0% ·
DMAC
Diamedica Therapeutics
 Sep 21, 2026 BUY Strong Buy
+92.0% avg upside
12 analysts
$12.00
51.07% Upside
 +9.4% ·
ALDX
Aldeyra Therapeutics
 Sep 21, 2026 HOLD Strong Buy
+1218.9% avg upside
21 analysts
$2.00
65.97% Upside
 -10.7% ·
KOD
Kodiak Sciences
 Sep 17, 2026 BUY Strong Buy
+62.3% avg upside
12 analysts
$58.00
79.21% Upside
 -0.5% ·
IMUX
Immunic
 Sep 10, 2026 BUY Strong Buy
+314.5% avg upside
22 analysts
$22.00
135.41% Upside
 -21.1% ·
IRD
Opus Genetics
 Sep 08, 2026 BUY Strong Buy
+146.7% avg upside
25 analysts
$8.00
68.07% Upside
 +19.4% ·
UPB
Upstream Bio, Inc.
 Sep 02, 2026 BUY Strong Buy
+469.8% avg upside
9 analysts
$36.00
571.70% Upside
 -17.2% ·
FDMT
4D Molecular Therapeutics
 Aug 14, 2026 BUY Strong Buy
+135.6% avg upside
16 analysts
$36.00
148.81% Upside
 +24.9% ·
MLYS
Mineralys Therapeutics, Inc.
 Aug 12, 2026 BUY Strong Buy
+77.1% avg upside
12 analysts
$56.00
116.60% Upside
 -0.6% ·
LENZ
LENZ Therapeutics
 Aug 12, 2026 BUY Buy
+439.0% avg upside
17 analysts
$38.00
870.68% Upside
 -21.6% ·
ARDX
Ardelyx
 Aug 07, 2026 BUY Strong Buy
+276.1% avg upside
21 analysts
$18.00
426.27% Upside
 -14.5% ·
TARS
Tarsus Pharmaceuticals
 Aug 07, 2026 BUY Strong Buy
+9.5% avg upside
17 analysts
$88.00
16.19% Upside
 +19.6% ·
AKBA
Akebia Therapeutics
 Aug 06, 2026 BUY Strong Buy
+913.1% avg upside
16 analysts
$6.00
569.43% Upside
 -4.0% ·
FBLG
FibroBiologics, Inc.
 Aug 04, 2026 BUY Buy
+557.1% avg upside
4 analysts
$6.00
331.75% Upside
 +74.0% ·
LYRA
Lyra Therapeutics
 Sep 17, 2025 HOLD Hold
+53900.0% avg upside
7 analysts
$16.00
7899.96% Upside
 -96.9% ·
CYVNY
Ceryvyn Therapeutics Limited
 Aug 22, 2025 HOLD Hold
+31951.3% avg upside
7 analysts
 — · ·
HYPD
Hyperion DeFi
 May 27, 2025 HOLD Strong Buy
+110.2% avg upside
8 analysts
 — +132.3% ·
RGNX
RegenXBio
 Oct 29, 2024 BUY Strong Buy
+410.8% avg upside
22 analysts
$39.00
427.08% Upside
 +41.7% ·
IRON
Disc Medicine
 Oct 21, 2022 HOLD Strong Buy
+35.5% avg upside
21 analysts
 — -20.7% ·
🔒 16 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Matthew Caufield — Frequently Asked Questions
How accurate are Matthew Caufield's stock ratings?
Based on the calls 13Foresight could measure, about 42% of Matthew's ratings were profitable over a one-year hold, with an average return of +0.1% per rating, or +29.1% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Matthew ranked on 13Foresight?
Matthew Caufield is currently ranked #1703 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Matthew cover?
Matthew most recently has ratings on SRZN, ZBIO, PHAT, DMAC, ALDX, KOD, IMUX, IRD, UPB, FDMT, MLYS, LENZ and 9 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.